JP2019524898A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524898A5
JP2019524898A5 JP2019531547A JP2019531547A JP2019524898A5 JP 2019524898 A5 JP2019524898 A5 JP 2019524898A5 JP 2019531547 A JP2019531547 A JP 2019531547A JP 2019531547 A JP2019531547 A JP 2019531547A JP 2019524898 A5 JP2019524898 A5 JP 2019524898A5
Authority
JP
Japan
Prior art keywords
human patient
disease
huntington
patient
ability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531547A
Other languages
English (en)
Japanese (ja)
Other versions
JP6912574B2 (ja
JP2019524898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/048461 external-priority patent/WO2018039477A1/en
Publication of JP2019524898A publication Critical patent/JP2019524898A/ja
Publication of JP2019524898A5 publication Critical patent/JP2019524898A5/ja
Priority to JP2021078504A priority Critical patent/JP2021119186A/ja
Application granted granted Critical
Publication of JP6912574B2 publication Critical patent/JP6912574B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531547A 2016-08-24 2017-08-24 機能低下を治療するためのプリドピジンの使用 Active JP6912574B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078504A JP2021119186A (ja) 2016-08-24 2021-05-06 機能低下を治療するためのプリドピジンの使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US62/379,175 2016-08-24
US201662395263P 2016-09-15 2016-09-15
US62/395,263 2016-09-15
US201662411511P 2016-10-21 2016-10-21
US62/411,511 2016-10-21
US201662416685P 2016-11-02 2016-11-02
US62/416,685 2016-11-02
PCT/US2017/048461 WO2018039477A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating functional decline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078504A Division JP2021119186A (ja) 2016-08-24 2021-05-06 機能低下を治療するためのプリドピジンの使用

Publications (3)

Publication Number Publication Date
JP2019524898A JP2019524898A (ja) 2019-09-05
JP2019524898A5 true JP2019524898A5 (cg-RX-API-DMAC7.html) 2019-10-17
JP6912574B2 JP6912574B2 (ja) 2021-08-04

Family

ID=61241181

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531547A Active JP6912574B2 (ja) 2016-08-24 2017-08-24 機能低下を治療するためのプリドピジンの使用
JP2021078504A Pending JP2021119186A (ja) 2016-08-24 2021-05-06 機能低下を治療するためのプリドピジンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078504A Pending JP2021119186A (ja) 2016-08-24 2021-05-06 機能低下を治療するためのプリドピジンの使用

Country Status (17)

Country Link
US (1) US11207310B2 (cg-RX-API-DMAC7.html)
EP (2) EP4516356A3 (cg-RX-API-DMAC7.html)
JP (2) JP6912574B2 (cg-RX-API-DMAC7.html)
CN (2) CN109923102B (cg-RX-API-DMAC7.html)
AU (2) AU2017315783C1 (cg-RX-API-DMAC7.html)
BR (1) BR112019003732A2 (cg-RX-API-DMAC7.html)
CA (2) CA3151507C (cg-RX-API-DMAC7.html)
CL (2) CL2019000485A1 (cg-RX-API-DMAC7.html)
DK (1) DK3504187T3 (cg-RX-API-DMAC7.html)
ES (1) ES3025836T3 (cg-RX-API-DMAC7.html)
FI (1) FI3504187T3 (cg-RX-API-DMAC7.html)
HU (1) HUE071008T2 (cg-RX-API-DMAC7.html)
IL (1) IL311081A (cg-RX-API-DMAC7.html)
MX (2) MX390627B (cg-RX-API-DMAC7.html)
PL (1) PL3504187T3 (cg-RX-API-DMAC7.html)
PT (1) PT3504187T (cg-RX-API-DMAC7.html)
WO (1) WO2018039477A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
CN110012661A (zh) * 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
US10138241B2 (en) 2016-09-15 2018-11-27 Boehringer Ingelheim International Gmbh Substituted benzamides as RIPK2 inhibitors
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3917380B1 (en) * 2019-01-31 2025-03-19 F. Hoffmann-La Roche AG Assessing progression of huntington's disease
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
SMT202600016T1 (it) * 2019-06-12 2026-03-09 Prilenia Neurotherapeutics Ltd Composizione contenente pridopidina e un suo analogo per il trattamento della malattia di huntington e dei suoi sintomi
JP7603713B2 (ja) * 2020-05-04 2024-12-20 プリレニア ニューロセラピューティクス リミテッド 選択的s1rアゴニストを使用するウイルス感染、疾患、又は障害の治療
CN116472043A (zh) 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
CA3214354A1 (en) * 2021-04-14 2022-10-20 Michael Hayden Treatment of prodromal huntington disease
WO2025164698A1 (ja) * 2024-01-31 2025-08-07 株式会社ケイファーマ ハンチントン病治療剤及び治療用組成物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
PE20071092A1 (es) 2005-12-08 2007-12-10 Aventis Pharma Inc Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070286902A1 (en) 2006-06-07 2007-12-13 Abrika Pharmaceuticals Dosage forms comprising a short acting sedative-hypnotic or salt thereof
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
WO2010008486A2 (en) * 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
BR112012006651B1 (pt) 2009-09-24 2021-11-03 Capsugel Belgium Nv Cápsula farmacêutica dura resistente a ácido e composição aquosa compreendendo goma de gelano e hpmc
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2710041A4 (en) 2011-05-18 2014-11-05 Parkinson S Inst ASSAY FOR DETERMINING LRRK2 ACTIVITY IN MORBUS PARKINSON
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US9744155B2 (en) * 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US20150209346A1 (en) 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015003812A (es) 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
CA2913781C (en) * 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
JP2020532517A (ja) 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤

Similar Documents

Publication Publication Date Title
Kaasenbrood et al. Opportunistic screening versus usual care for diagnosing atrial fibrillation in general practice: a cluster randomised controlled trial
CN109923102B (zh) 普利多匹定用于治疗功能下降的用途
Avivi-Arber et al. Widespread volumetric brain changes following tooth loss in female mice
Yarnall et al. Parkinson's disease
US20110130466A1 (en) Use of rasagiline for the treatment of progressive supranuclear palsy
JP2019524897A (ja) ジストニアを治療するためのプリドピジンの使用
JP2018506569A (ja) 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
JP2019529411A (ja) 不安症およびうつ病の治療のためのプリドピジンの使用
Fava et al. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD)
Weydt et al. Clinical trials in spinal and bulbar muscular atrophy—past, present, and future
JP5856725B2 (ja) うつ病治療用または予防用医薬組成物
CN117202906A (zh) 前驱亨廷顿病的治疗
CN120284934A (zh) 一种组合物在制备药物中的应用
KR20240161650A (ko) 조현병 환자에서 재발을 예방하는 데 있어서 롤루페리돈의 용도
ZHANG et al. Efficacy of acupuncture in combination with medicine for mild cognitive impairment after cerebral infarction: a randomized controlled trial
Fujihara et al. The impact of lesion location on medication self-management ability in patients with cerebrovascular disease
US20260091028A1 (en) Method of treating amyotrophic lateral sclerosis with pridopidine
JP2009007278A (ja) 線維筋痛症の治療薬
Malaspina et al. Disorders of the Motor Cells: The Motor Neuron Diseases
Ng et al. Motor neuron disease: causes, classification and treatments
Chandradevan et al. Acute Post-stroke Hemiparkinsonism and Hemiparesis: A Unique Case with Successful Therapy
Badyal et al. Safety and efficacy of duloxetine versus venlafaxine in major depression in Indian patients
Waterman Extending the effects of pulmonary rehabilitation in a community setting
Brunton A comprehensive approach to Parkinson's disease: How to manage fluctuating motor and nonmotor symptoms
Seña et al. Identifying Health Inequities among Persons Identified with Chronic Hepatitis C Infections through a Public Health Program